| Potential drug interactions and duplicate prescriptions among cancer patients RP Riechelmann, IF Tannock, L Wang, ED Saad, NA Taback, ... Journal of the National Cancer Institute 99 (8), 592-600, 2007 | 429 | 2007 |
| Molecular profiling of advanced solid tumors and patient outcomes with genotype-matched clinical trials: the Princess Margaret IMPACT/COMPACT trial TL Stockley, AM Oza, HK Berman, NB Leighl, JJ Knox, FA Shepherd, ... Genome medicine 8, 1-12, 2016 | 253 | 2016 |
| A retrospective study assessing the incidence, risk factors and comorbidities of pamidronate-related necrosis of the jaws in multiple myeloma patients F Jadu, L Lee, M Pharoah, D Reece, L Wang Annals of Oncology 18 (12), 2015-2019, 2007 | 240 | 2007 |
| Adavosertib plus gemcitabine for platinum-resistant or platinum-refractory recurrent ovarian cancer: a double-blind, randomised, placebo-controlled, phase 2 trial S Lheureux, MC Cristea, JP Bruce, S Garg, M Cabanero, ... The Lancet 397 (10271), 281-292, 2021 | 166 | 2021 |
| Evolution of the randomized controlled trial in oncology over three decades CM Booth, DW Cescon, L Wang, IF Tannock, MK Krzyzanowska Journal of Clinical Oncology 26 (33), 5458-5464, 2008 | 166 | 2008 |
| Potential drug interactions in cancer patients receiving supportive care exclusively RP Riechelmann, C Zimmermann, SN Chin, L Wang, A O'Carroll, ... Journal of pain and symptom management 35 (5), 535-543, 2008 | 165 | 2008 |
| Phase II trial of the histone deacetylase inhibitor belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumours HJ Mackay, H Hirte, T Colgan, A Covens, K MacAlpine, P Grenci, L Wang, ... European Journal of Cancer 46 (9), 1573-1579, 2010 | 158 | 2010 |
| Expression analysis of 6p22 genomic gain in retinoblastoma M Orlic, CE Spencer, L Wang, BL Gallie Genes, Chromosomes and Cancer 45 (1), 72-82, 2006 | 156 | 2006 |
| A phase II study of sunitinib in recurrent and/or metastatic adenoid cystic carcinoma (ACC) of the salivary glands: current progress and challenges in evaluating molecularly … NG Chau, SJ Hotte, EX Chen, SF Chin, S Turner, L Wang, LL Siu Annals of oncology 23 (6), 1562-1570, 2012 | 155 | 2012 |
| Translating clinical trials to clinical practice: outcomes of men with metastatic castration resistant prostate cancer treated with docetaxel and prednisone in and out of … AJ Templeton, FE Vera-Badillo, L Wang, M Attalla, P De Gouveia, ... Annals of oncology 24 (12), 2972-2977, 2013 | 152 | 2013 |
| Hyperprogressive disease in early‐phase immunotherapy trials: clinical predictors and association with immune‐related toxicities Y Kanjanapan, D Day, L Wang, H Al‐Sawaihey, E Abbas, A Namini, ... Cancer 125 (8), 1341-1349, 2019 | 147 | 2019 |
| Association of ipilimumab with safety and antitumor activity in women with metastatic or recurrent human papillomavirus–related cervical carcinoma S Lheureux, MO Butler, B Clarke, MC Cristea, LP Martin, K Tonkin, ... JAMA oncology 4 (7), e173776-e173776, 2018 | 139 | 2018 |
| Phase II clinical trial of adoptive cell therapy for patients with metastatic melanoma with autologous tumor-infiltrating lymphocytes and low-dose interleukin-2 LT Nguyen, SD Saibil, V Sotov, MX Le, L Khoja, D Ghazarian, L Bonilla, ... Cancer Immunology, Immunotherapy 68, 773-785, 2019 | 135 | 2019 |
| A phase 2 trial of sunitinib in patients with progressive paraganglioma or pheochromocytoma: the SNIPP trial GM O’Kane, S Ezzat, AM Joshua, I Bourdeau, R Leibowitz-Amit, HJ Olney, ... British journal of cancer 120 (12), 1113-1119, 2019 | 117 | 2019 |
| Predictors of liver toxicity following stereotactic body radiation therapy for hepatocellular carcinoma M Velec, CR Haddad, T Craig, L Wang, P Lindsay, J Brierley, A Brade, ... International Journal of Radiation Oncology* Biology* Physics 97 (5), 939-946, 2017 | 114 | 2017 |
| Reporting of serious adverse drug reactions of targeted anticancer agents in pivotal phase III clinical trials B Seruga, L Sterling, L Wang, IF Tannock Journal of clinical oncology 29 (2), 174-185, 2011 | 112 | 2011 |
| Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas A Stathis, SJ Hotte, EX Chen, HW Hirte, AM Oza, P Moretto, S Webster, ... Clinical Cancer Research 17 (6), 1582-1590, 2011 | 106 | 2011 |
| The association between EGFR variant III, HPV, p16, c-MET, EGFR gene copy number and response to EGFR inhibitors in patients with recurrent or metastatic squamous cell … NG Chau, B Perez-Ordonez, K Zhang, NA Pham, J Ho, T Zhang, ... Head & neck oncology 3, 1-11, 2011 | 105 | 2011 |
| A phase II trial of sorafenib in first-line metastatic urothelial cancer: a study of the PMH Phase II Consortium SS Sridhar, E Winquist, A Eisen, SJ Hotte, E McWhirter, IF Tannock, ... Investigational new drugs 29, 1045-1049, 2011 | 103 | 2011 |
| Phase II clinical and pharmacokinetic study of aflibercept in patients with previously treated metastatic colorectal cancer PA Tang, SJ Cohen, C Kollmannsberger, G Bjarnason, K Virik, ... Clinical Cancer Research 18 (21), 6023-6031, 2012 | 101 | 2012 |
